These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37474005)

  • 1. The Clinical and Biological Significance of Estrogen Receptor-Low Positive Breast Cancer.
    Makhlouf S; Althobiti M; Toss M; Muftah AA; Mongan NP; Lee AHS; Green AR; Rakha EA
    Mod Pathol; 2023 Oct; 36(10):100284. PubMed ID: 37474005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
    Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
    BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accurate Estrogen Receptor Quantification in Patients with Negative and Low-Positive Estrogen-Receptor-Expressing Breast Tumors: Sub-Analyses of Data from Two Clinical Studies.
    Dixon JM; Cameron DA; Arthur LM; Axelrod DM; Renshaw L; Thomas JS; Turnbull A; Young O; Loman CA; Jakubowski D; Baehner FL; Singh B
    Adv Ther; 2019 Apr; 36(4):828-841. PubMed ID: 30859501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry.
    Iwamoto T; Booser D; Valero V; Murray JL; Koenig K; Esteva FJ; Ueno NT; Zhang J; Shi W; Qi Y; Matsuoka J; Yang EJ; Hortobagyi GN; Hatzis C; Symmans WF; Pusztai L
    J Clin Oncol; 2012 Mar; 30(7):729-34. PubMed ID: 22291085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen-Receptor-Low-Positive Breast Cancer: Pathological and Clinical Perspectives.
    Malainou CP; Stachika N; Damianou AK; Anastopoulos A; Ploumaki I; Triantafyllou E; Drougkas K; Gomatou G; Kotteas E
    Curr Oncol; 2023 Nov; 30(11):9734-9745. PubMed ID: 37999126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.
    Wu JR; Zhao Y; Zhou XP; Qin X
    Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer.
    Ohara AM; Naoi Y; Shimazu K; Kagara N; Shimoda M; Tanei T; Miyake T; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2019 Feb; 173(3):533-543. PubMed ID: 30361874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6.
    Filipits M; Rudas M; Singer CF; Fitzal F; Bago-Horvath Z; Greil R; Balic M; Lax SF; Halper S; Hulla W; Wu NC; Liu X; Weidler J; Bates M; Hlauschek D; Gnant M; Dubsky P
    ESMO Open; 2021 Aug; 6(4):100228. PubMed ID: 34371382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Further evidence to support bimodality of oestrogen receptor expression in breast cancer.
    Muftah AA; Aleskandarany M; Sonbul SN; Nolan CC; Diez Rodriguez M; Caldas C; Ellis IO; Green AR; Rakha EA
    Histopathology; 2017 Feb; 70(3):456-465. PubMed ID: 27648723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer.
    Chen L; Chen Y; Xie Z; Luo J; Wang Y; Zhou J; Huang L; Li H; Wang L; Liu P; Shu M; Zhang W; Ke Z
    Breast Cancer Res Treat; 2022 Aug; 194(3):517-529. PubMed ID: 35789315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies.
    Zeng J; Piscuoglio S; Aggarwal G; Magda J; Friedlander MA; Murray M; Akram M; Reis-Filho JS; Weigelt B; Edelweiss M
    Cancer Cytopathol; 2020 Feb; 128(2):133-145. PubMed ID: 31883437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
    Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
    BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune and Gene-expression Profiling in Estrogen Receptor Low and Negative Early Breast Cancer.
    Massa D; Vernieri C; Nicolè L; Criscitiello C; Boissière-Michot F; Guiu S; Bobrie A; Griguolo G; Miglietta F; Vingiani A; Lobefaro R; Taurelli Salimbeni B; Pinato C; Schiavi F; Brich S; Pescia C; Fusco N; Pruneri G; Fassan M; Curigliano G; Guarneri V; Jacot W; Dieci MV
    J Natl Cancer Inst; 2024 Jul; ():. PubMed ID: 39083015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
    Li Y; Yang D; Yin X; Zhang X; Huang J; Wu Y; Wang M; Yi Z; Li H; Li H; Ren G
    JAMA Netw Open; 2020 Jan; 3(1):e1918160. PubMed ID: 31899528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
    Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
    Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA.12 Trial and BC Cohort.
    Chapman JA; Nielsen TO; Ellis MJ; Bernard P; Chia S; Gelmon KA; Pritchard KI; Le Maitre A; Goss PE; Leung S; Shepherd LE; Bramwell VH
    Breast Cancer Res; 2013; 15(4):R71. PubMed ID: 23972025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implication of low estrogen receptor (ER-low) expression in breast cancer.
    Reinert T; Cascelli F; de Resende CAA; Gonçalves AC; Godo VSP; Barrios CH
    Front Endocrinol (Lausanne); 2022; 13():1015388. PubMed ID: 36506043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of breast cancer surrogate subtyping using a closed-system RT-qPCR breast cancer assay and immunohistochemistry on 100 core needle biopsies with matching surgical specimens.
    Janeva S; Parris TZ; Nasic S; De Lara S; Larsson K; Audisio RA; Olofsson Bagge R; Kovács A
    BMC Cancer; 2021 Apr; 21(1):439. PubMed ID: 33879115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Real-World Data Retrospective Cohort Study of Low Estrogen Receptor-Positive Early Breast Cancer: Natural History and Treatment Outcomes.
    Bari S; Boulware D; Li J; Loftus L; Soyano Muller A; Jameel Z; Khong H; Czerniecki BJ; Costa RLB
    Breast Cancer (Dove Med Press); 2022; 14():199-210. PubMed ID: 35967746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
    Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
    Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.